Metabolic manifestations of insulin deficiency do not occur without glucagon action

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 37, 2012, Pages 14972-14976

  Lee, Young ^a   Berglund, Eric D ^b   Wang, May Yun ^a   Fu, Xiaorong ^b   Yu, Xinxin ^a   Charron, Maureen J ^c   Burgess, Shawn C ^b   Unger, Roger H ^a,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Glucagon receptor knockout; Glucose turnover; Type 1 diabetes

Indexed keywords

ACETYL COA OXIDASE; ACETYL COENZYME A CARBOXYLASE; ADENOVIRUS VECTOR; CARNITHINE PALMITYOL TRANSFERASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIACYL GLYCEROL TRANSFERASE 2; FATTY ACID SYNTHASE; GLUCAGON; GLUCAGON RECEPTOR; GLYCEROL PHOSPHATE ACYL TRANSFERASE; INSULIN; PHOSPHOENOL PYRUVATE CARBOXY KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLYCOGEN LIVER LEVEL; HYPERGLYCEMIA; INSULIN DEFICIENCY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANIMALS; BLOOD GLUCOSE; CHROMATOGRAPHY, GAS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DIABETES MELLITUS, EXPERIMENTAL; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; GLUCAGON; IMMUNOBLOTTING; INSULIN; LIVER; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GLUCAGON;

ADENOVIRIDAE; MUS;

EID: 84866299596     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1205983109     Document Type: Article

References (41)

1. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (1922) Pancreatic extracts inthe treatment of diabetes mellitus. Can Med Assoc J 12:141-146.
2. Kimball CP, Murlin JR (1923) Aqueous extracts of pancreas. III. Some precipitationreactions of insulin. J Biol Chem 58:337-346.
3. Baum J, Simons BE, Jr., Unger RH, Madison LL (1962) Localization of glucagon in thealpha cells in the pancreatic islet by immunofluorescent technics. Diabetes 11:371-374.
4. Blazquez E, et al. (1976) Gastric A-cell function in insulin-deprived depancreatizeddogs. Endocrinology 99:1182-1188.
5. Cherrington AD, Chiasson JL, Liljenquist JE, Lacy WW, Park CR (1978) Control of hepaticglucose output by glucagon and insulin in the intact dog. Biochem Soc Symp (43):31-45.
6. Exton JH, et al. (1970) The hormonal control of hepatic gluconeogenesis. Recent ProgHorm Res 26:411-461.
7. Sutherland EW, De Duve C (1948) Origin and distribution of the hyperglycemic-glycogenolyticfactor of the pancreas. J Biol Chem 175:663-674.
8. Unger RH, Eisentraut AM, Madison LL (1963) The effects of total starvation upon thelevels of circulating glucagon and insulin in man. J Clin Invest 42:1031-1039.
9. Unger RH, Eisentraut AM, McCALL MS, Madison LL (1962) Measurements of endogenousglucagon in plasma and the influence of blood glucose concentration upon itssecretion. J Clin Invest 41:682-689.
10. Samols E, Tyler J, Marks V (1972) Glucagon insulin interrelationships. Glucagon. MolecularPhysiology and Therapeutic Clinical Implication, eds Lefebvre PJ, Unger RH(Pergamon, Oxford), pp 157-174.
11. Müller WA, Faloona GR, Unger RH (1973) Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med 54:52-57.
12. Muller WA, et al. (1978) Extrapancreatic glucagon and glucagonlike immunoreactivityin depancreatized dogs. A quantitative assessment of secretion rates and anatomicaldelineation of sources. J Clin Invest 62:124-132.
13. Huseman C, Johanson A, Varma M, Blizzard RM (1978) Congenital lipodystrophy: Anendocrine study in three siblings. I. Disorders of carbohydrate metabolism. J Pediatr93:221-226.
14. Unger RH (1976) The Banting Memorial Lecture 1975. Diabetes and the alpha cell.Diabetes 25:136-151.
15. Dobbs R, et al. (1975) Glucagon: Role in the hyperglycemia of diabetes mellitus. Science187:544-547.
16. Gerich JE, et al. (1975) Prevention of human diabetic ketoacidosis by somatostatin.Evidence for an essential role of glucagon. N Engl J Med 292:985-989.
17. Raskin P, Unger RH (1978) Hyperglucagonemia and its suppression. Importance in themetabolic control of diabetes. N Engl J Med 299:433-436.
18. Brand CL, et al. (1994) Immunoneutralization of endogenous glucagon with monoclonalglucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabeticrats. Diabetologia 37:985-993.
19. Unger RH, Orci L (1975) The essential role of glucagon in the pathogenesis of diabetesmellitus. Lancet 1:14-16.
20. Brazeau P, et al. (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactivepituitary growth hormone. Science 179:77-79.
21. Fölsch UR, Lankisch PG, Creutzfeldt W (1978) Effect of somatostatin on basal and stimulated pancreatic secretion in the rat. Digestion 17:194-203.
22. Halaas JL, et al. (1995) Weight-reducing effects of the plasma protein encoded by theobese gene. Science 269:543-546.
23. Flier JS (1997) Leptin expression and action: New experimental paradigms. Proc NatlAcad Sci USA 94:4242-4245.
24. Drucker DJ (2002) Biological actions and therapeutic potential of the glucagon-likepeptides. Gastroenterology 122:531-544.
25. D'Alessio DA, Sandoval DA, Seeley RJ (2005) New ways in which GLP-1 can regulateglucose homeostasis. J Clin Invest 115:3406-3408.
26. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH (2011) Glucagon receptor knockoutprevents insulin-defi cient type 1 diabetes in mice. Diabetes 60:391-397.
27. Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35years of research but the enigma remains. Endocr Rev 28:84-116.
28. Gelling RW, et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreaticalpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA100:1438-1443.
29. Koo SH, et al. (2005) The CREB coactivator TORC2 is a key regulator of fasting glucosemetabolism. Nature 437:1109- 1111.
30. Berglund ED, et al. (2009) Hepatic energy state is regulated by glucagon receptorsignaling in mice. J Clin Invest 119:2412-2422.
31. Hachey DL, Parsons WR, McKay S, Haymond MW (1999) Quantitation of monosaccharideisotopic enrichment in physiologic fluids by electron ionization or negativechemical ionization GC/MS using di-O-isopropylidene derivatives. Anal Chem 71:4734-4739.
32. Djuric SW, Grihalde N, Lin CW (2002) Glucagon receptor antagonists for the treatmentof type II diabetes: Current prospects. Curr Opin Investig Drugs 3:1617-1623.
33. Sloop KW, Michael MD, Moyers JS (2005) Glucagon as a target for the treatment oftype 2 diabetes. Expert Opin Ther Targets 9:593-600.
34. Braaten JT, Faloona GR, Unger RH (1974) The effect of insulin on the alpha-cellresponse to hyperglycemia in long-standing alloxan diabetes. J Clin Invest 53(4):1017-1021.
35. Wang MY, et al. (2010) Leptin therapy in insulin-defi cient type I diabetes. Proc NatlAcad Sci USA 107:4813-4819.
36. Unger RH, Cherrington AD (2012) Glucagonocentric restructuring of diabetes: Apathophysiologic and therapeutic makeover. J Clin Invest 122:4-12.
37. Kawamori D, et al. (2009) Insulin signaling in alpha cells modulates glucagon secretionin vivo. Cell Metab 9:350-361.
38. Unger RH, Orci L (2010) Paracrinology of islets and the paracrinopathy of diabetes.Proc Natl Acad Sci USA 107:16009-16012.
39. Jamison RA, et al. (2011) Hyperglucagonemia precedes a decline in insulin secretionand causes hyperglycemia in chronically glucose-infused rats. Am J Physiol EndocrinolMetab 301:E1174-E1183.
40. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation andpurification of total lipides from animal tissues. J Biol Chem 226:497-509.
41. Berglund ED, et al. (2012) Direct leptin action on POMC neurons regulates glucosehomeostasis and hepatic insulin sensitivity in mice. J Clin Invest 122:1000-1009.